Vor Biopharma Inc (VOR)

Mar 20, 2025, 4:05 PM EDT - 13 days ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Feb 13, 2025, 8:00 AM EST - 6 weeks ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 3, 2025, 8:00 AM EST - 2 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 9:00 AM EST - 3 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Dec 27, 2024, 9:00 AM EST - 3 months ago

Vor Bio Announces $55.6 Million Private Placement

Dec 9, 2024, 7:30 AM EST - 4 months ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Sep 30, 2024, 7:00 AM EDT - 6 months ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 6, 2024, 9:35 AM EDT - 7 months ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 5, 2024, 4:01 PM EDT - 7 months ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Aug 28, 2024, 8:00 AM EDT - 7 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Aug 8, 2024, 4:05 PM EDT - 8 months ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 2, 2024, 4:01 PM EDT - 8 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2024, 4:05 PM EDT - 11 months ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 4:01 PM EDT - 11 months ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Nov 27, 2023, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 9, 2023, 4:01 PM EST - 1 year ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Nov 7, 2023, 4:05 PM EST - 1 year ago

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 2, 2023, 9:01 AM EDT - 1 year ago

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 1, 2023, 8:00 AM EDT - 1 year ago

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Jul 5, 2023, 8:51 AM EDT - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CBUS LUCY

Jun 9, 2023, 7:30 AM EDT - 1 year ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

May 11, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

Mar 27, 2023, 3:13 PM EDT - 2 years ago

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Feb 16, 2023, 12:00 PM EST - 2 years ago

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Jan 19, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Jan 12, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Dec 7, 2022, 7:45 AM EST - 2 years ago

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Dec 7, 2022, 7:30 AM EST - 2 years ago

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Nov 10, 2022, 4:15 PM EST - 2 years ago

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Oct 12, 2022, 8:00 AM EDT - 2 years ago

Vor Bio Appoints Eyal C. Attar, M.D.

Oct 11, 2022, 8:00 AM EDT - 2 years ago

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Sep 28, 2022, 8:00 AM EDT - 2 years ago

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Aug 11, 2022, 4:15 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Jun 10, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

May 12, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

May 5, 2022, 8:00 AM EDT - 3 years ago

Vor to Participate in Two Upcoming Investor Conferences

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

Apr 14, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Announces Retirement of Chief Medical Officer

Mar 22, 2022, 10:10 AM EDT - 3 years ago

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

Mar 14, 2022, 4:30 PM EDT - 3 years ago

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Feb 28, 2022, 8:00 AM EST - 3 years ago

Vor to Participate in Three Upcoming Investor Conferences

Feb 11, 2022, 8:00 AM EST - 3 years ago

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Nov 29, 2021, 8:00 AM EST - 3 years ago

Vor to Participate in the JMP Securities Hematology and Oncology Summit

Nov 19, 2021, 4:01 PM EST - 3 years ago

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference